Illumina is enhancing customer capabilities to analyze and interpret the data produced by our sequencing systems with the acquisition of BlueBee, a cloud-based software company that provides genomics analysis solutions for research and clinical customers. Based in the Netherlands, BlueBee has developed a regulatory compliant, secure cloud platform that simplifies access to data and tools, enabling users to easily extract insights from genomic data. This cloud capability is expected to lower the cost of storing, sharing and managing the enormous volumes of genomic data that streams from Illumina’s installed base of more than 15,000 sequencing systems.
“Combining BlueBee and Illumina software products provides the most scalable, efficient, and extensible genomic analysis solutions for both clinical and translational research use cases. BlueBee truly brings unique capabilities, while ensuring secure deployment of clinical informatics across the globe, and together we hope to deliver an unprecedented learning environment in order to unlock the full potential of genomic insights.”
“Together with Illumina we can create a sample to insight ecosystem for genomics while further expanding the utility of sequencing data. Our team is encouraged at the prospect of joining Illumina where we believe we can merge high power computing and advanced data science technologies to help propel genomics forward and deliver on its clinical promise.”
“With Illumina’s acquisition of BlueBee, we now have the power and capability to streamline workflow configuration and optimize costs via data lifecycle management tools. We chose the most widely used testing platform in Illumina and the ‘best in class’ cloud-computing provider in BlueBee in order to efficiently decentralize both MammaPrint and Blueprint in Europe, Asia and North America, ensuring secure, accurate and timely testing. Having these two partners now as part of one company will allow all parties to accelerate growth, expand our offering and, most importantly, help women with breast cancer around the world.”
— Mark Straley, CEO of Agendia
“IDT has a great history of partnership with BlueBee, so we are pleased to learn their innovative platform will join the industry-leading sequencing technology provided by our strategic partner Illumina. This combination can drive the entire global genomics ecosystem forward with robust, scalable architecture that supports customers’ ability to scale analytic insights globally.”
— Trey Martin, President of Integrated DNA Technologies, Inc. (IDT)